MCID: PRM126
MIFTS: 59

Primary Peritoneal Carcinoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

MalaCards integrated aliases for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 55 36 69
Serous Surface Papillary Carcinoma 55 69
Extra-Ovarian Primary Peritoneal Carcinoma 55
Primary Peritoneal Serous Adenocarcinoma 69
Primary Peritoneal Serous Carcinoma 55
Eoppc 55
Ppc 55

Characteristics:

Orphanet epidemiological data:

55
primary peritoneal carcinoma
Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

Orphanet 55 ORPHA168829
ICD10 via Orphanet 33 C48.2
KEGG 36 H01665
UMLS 69 C1514428

Summaries for Primary Peritoneal Carcinoma

MalaCards based summary : Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to papillary serous adenocarcinoma and peritonitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, t cells and liver, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Wikipedia : 72 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

Related Diseases for Primary Peritoneal Carcinoma

Diseases in the Peritoneal Benign Neoplasm family:

Primary Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 181)
# Related Disease Score Top Affiliating Genes
1 papillary serous adenocarcinoma 32.8 BRCA1 PGR TP53
2 peritonitis 30.7 CXCL8 IFNG IL10 MUC16
3 papillary carcinoma 29.8 ERBB2 PGR RET
4 adenocarcinoma 29.3 EGFR ERBB2 RET TP53 VEGFA
5 endometriosis 28.9 CXCL8 MUC16 PGR VEGFA
6 ovarian cancer 1 27.9 BRCA1 BRCA2 EGFR ERBB2 MUC16 PGR
7 ovarian cancer 27.8 BRCA1 BRCA2 EGFR ERBB2 ERCC1 MUC16
8 ovary papillary carcinoma 11.3
9 hereditary site-specific ovarian cancer syndrome 10.6 BRCA1 BRCA2
10 brca1 hereditary breast and ovarian cancer syndrome 10.6 BRCA1 BRCA2
11 breast reconstruction 10.6 BRCA1 BRCA2
12 breast-ovarian cancer, familial 1 10.5 BRCA1 BRCA2
13 endometrium carcinoma in situ 10.5 PGR TP53
14 vestibular gland benign neoplasm 10.5 PGR TP53
15 bartholin's gland adenoma 10.5 PGR TP53
16 scirrhous adenocarcinoma 10.5 ERBB2 PGR
17 breast apocrine carcinoma 10.5 ERBB2 PGR
18 hyperlucent lung 10.5 IFNG IL10
19 squamous cell carcinoma of the oropharynx 10.5 IL10 TP53
20 nosophobia 10.5 BRCA1 BRCA2 PGR
21 cancerophobia 10.5 BRCA1 BRCA2 PGR
22 glassy cell carcinoma of the cervix 10.4 ERBB2 PGR
23 tungiasis 10.4 CXCL8 IL10
24 dysgerminoma of ovary 10.4 BRCA1 BRCA2 PGR
25 mutagen sensitivity 10.4 BRCA1 BRCA2 TP53
26 tetraploidy 10.4 BRCA2 TP53
27 hereditary breast ovarian cancer syndrome 10.4 BRCA1 BRCA2 TP53
28 tuberculous salpingitis 10.4 BRCA1 BRCA2 ERBB2
29 cowden disease 10.4 BRCA1 BRCA2 RET
30 brain ependymoma 10.4 EGFR TP53
31 clonorchiasis 10.4 CXCL8 IFNG IL10
32 scabies 10.4 CXCL8 IL10
33 aseptic meningitis 10.4 CXCL8 IFNG IL10
34 female reproductive endometrioid cancer 10.4 PGR TP53
35 cytomegalovirus infection 10.3 CXCL8 IFNG IL10
36 breast malignant phyllodes tumor 10.3 PGR TP53
37 breast medullary carcinoma 10.3 BRCA1 ERBB2 PGR
38 acute transverse myelitis 10.3 CXCL8 IL10
39 breast intraductal proliferative lesion 10.3 EGFR ERBB2
40 brucellosis 10.3 CXCL8 IFNG IL10
41 dengue hemorrhagic fever 10.3 CXCL8 IFNG IL10
42 bronchiolitis obliterans 10.3 CXCL8 IFNG IL10
43 allergic contact dermatitis 10.3 CXCL8 IFNG IL10
44 olfactory groove meningioma 10.3 PGR TP53
45 lymphadenitis 10.3 CXCL8 IFNG IL10
46 gastroenteritis 10.3 CXCL8 IFNG IL10
47 glioma susceptibility 1 10.3 ERBB2 TP53
48 autoinflammation, lipodystrophy, and dermatosis syndrome 10.3 CXCL8 IFNG IL10
49 triple-receptor negative breast cancer 10.3 BRCA1 ERBB2 PGR
50 osteomyelitis 10.3 CXCL8 IFNG IL10

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to Primary Peritoneal Carcinoma

Symptoms & Phenotypes for Primary Peritoneal Carcinoma

Human phenotypes related to Primary Peritoneal Carcinoma:

55 31 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 55 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 constipation 55 31 hallmark (90%) Very frequent (99-80%) HP:0002019
3 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
4 peritonitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002586
5 neoplasm 55 31 hallmark (90%) Very frequent (99-80%) HP:0002664
6 abdominal distention 55 31 hallmark (90%) Very frequent (99-80%) HP:0003270

GenomeRNAi Phenotypes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 IL10
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 ERCC1 IFNG IL10 PGR RET TP53
2 embryo MP:0005380 10.31 BRCA2 EGFR ERBB2 ERCC1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.31 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
4 behavior/neurological MP:0005386 10.3 BRCA1 BRCA2 ERBB2 ERCC1 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.3 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
6 cardiovascular system MP:0005385 10.29 BRCA1 CXCL10 EGFR ERBB2 IFNG IL10
7 hematopoietic system MP:0005397 10.29 EGFR ERCC1 IFNG IL10 PGR RET
8 immune system MP:0005387 10.26 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
9 mortality/aging MP:0010768 10.26 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
10 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
11 integument MP:0010771 10.21 IL10 PGR TP53 VEGFA BRCA1 BRCA2
12 neoplasm MP:0002006 10.17 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
13 muscle MP:0005369 10.16 BRCA1 EGFR ERBB2 ERCC1 IFNG IL10
14 limbs/digits/tail MP:0005371 10.15 BRCA1 BRCA2 EGFR ERBB2 IL10 PGR
15 nervous system MP:0003631 10.1 TP53 VEGFA BRCA1 BRCA2 CXCL10 EGFR
16 normal MP:0002873 10.02 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
17 no phenotypic analysis MP:0003012 9.91 EGFR IFNG IL10 PGR RET TP53
18 reproductive system MP:0005389 9.9 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
19 renal/urinary system MP:0005367 9.8 RET TP53 VEGFA BRCA1 EGFR ERCC1
20 respiratory system MP:0005388 9.56 BRCA1 EGFR ERBB2 IFNG IL10 RET
21 skeleton MP:0005390 9.32 TP53 VEGFA BRCA1 BRCA2 EGFR ERBB2

Drugs & Therapeutics for Primary Peritoneal Carcinoma

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
7
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
10
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
11
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
12
Olaparib Approved Phase 2, Phase 3, Phase 1 763113-22-0 23725625
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
16
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
20
Cediranib Investigational Phase 2, Phase 3, Phase 1 288383-20-0 9933475
21
Maleic acid Experimental Phase 2, Phase 3, Phase 1 110-16-7 444266
22 Steroid Synthesis Inhibitors Phase 2, Phase 3,Phase 1
23 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
24 Hormone Antagonists Phase 3,Phase 2,Phase 1
25 Hormones Phase 3,Phase 2,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Estrogen Antagonists Phase 3,Phase 2
29 Estrogens Phase 3,Phase 2
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Aromatase Inhibitors Phase 2, Phase 3
36 Alkylating Agents Phase 3,Phase 2,Phase 1
37 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
38 Micronutrients Phase 3,Phase 2,Phase 1
39 Selective Estrogen Receptor Modulators Phase 3,Phase 2
40 Mitogens Phase 2, Phase 3, Phase 1
41 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
43 Trace Elements Phase 3,Phase 2,Phase 1
44 Vitamin B Complex Phase 3,Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
46 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
47 Vitamins Phase 3,Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2, Phase 3, Phase 1
49 Endothelial Growth Factors Phase 2, Phase 3, Phase 1
50 Estrogen Receptor Modulators Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 232)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
2 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
3 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
4 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
5 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
6 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
7 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
8 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
9 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
10 PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer Recruiting NCT02631876 Phase 3 IMGN853;Paclitaxel;Doxorubicin;Topotecan
11 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
12 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
13 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
14 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Active, not recruiting NCT01506856 Phase 2, Phase 3 Paclitaxel(intravenous) + Carboplatin(intravenous);Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
15 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
16 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
17 Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery Not yet recruiting NCT03373058 Phase 3 adjuvant chemotherapy
18 Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer Not yet recruiting NCT03180177 Phase 3 neoadjuvant chemotherapy;adjuvant chemotherapy
19 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
20 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
21 Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer Terminated NCT00047632 Phase 3 Interferon gamma-1b
22 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
23 Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer Unknown status NCT02125513 Phase 2 carboplatin and paclitaxel followed by surgery
24 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
25 Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer Unknown status NCT01180504 Phase 2
26 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
27 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT01381861 Phase 2
28 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma Completed NCT00868192 Phase 2 Pemetrexed;Bevacizumab
29 Study of Ramucirumab in Ovarian Cancer Completed NCT00721162 Phase 2
30 A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00671788 Phase 2 Dasatinib
31 Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00193297 Phase 2 Topotecan;Paclitaxel;Carboplatin
32 Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00183794 Phase 2 Docetaxel and Gemcitabine
33 Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma Completed NCT00179712 Phase 1, Phase 2 CC-5013;topotecan
34 Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer Completed NCT00407563 Phase 2 Bevacizumab;Abraxane
35 Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00093626 Phase 2 Sorafenib Tosylate
36 Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00054119 Phase 2 Cositecan
37 MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma Completed NCT00853307 Phase 2 MLN8237
38 Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00072566 Phase 2 Cyclophosphamide
39 Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01039207 Phase 2
40 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer Completed NCT00034151 Phase 2 S-8184 Paclitaxel Injectable Emulsion
41 Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01305213 Phase 2 Fosbretabulin Tromethamine
42 Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Completed NCT00436644 Phase 2 Lapatinib;Topotecan
43 A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian Completed NCT01952249 Phase 1, Phase 2 Demcizumab;Taxol
44 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
45 Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women Completed NCT01227928 Phase 2 Pazopanib;Placebo comparator
46 Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer Completed NCT00420381 Phase 2 enzastaurin
47 Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer Completed NCT01196559 Phase 2 Vinorelbine and Gemcitabine
48 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00459290 Phase 2 mifepristone
49 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00083122 Phase 2 cisplatin;alvocidib;cisplatin/flavopiridol
50 Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00026091 Phase 2 fenretinide

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

Anatomical Context for Primary Peritoneal Carcinoma

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

38
Breast, T Cells, Liver, Endothelial, Bone, Brain, Testes

Publications for Primary Peritoneal Carcinoma

Articles related to Primary Peritoneal Carcinoma:

(show top 50) (show all 127)
# Title Authors Year
1
Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. ( 29324533 )
2018
2
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. ( 28698009 )
2017
3
Brain metastasis from primary peritoneal carcinoma: Case report and literature review. ( 28279555 )
2017
4
Letter to the Editor on "Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?" Int J Gynecol Cancer 2015;25: 1201-1207. ( 26807559 )
2016
5
Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma. ( 26722051 )
2016
6
Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient. ( 27547810 )
2016
7
Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients. ( 28008196 )
2016
8
Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology. ( 27807506 )
2016
9
Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature. ( 27354995 )
2016
10
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma? ( 26035124 )
2015
11
Primary peritoneal serous papillary carcinoma presenting as a large mesenteric mass mistaken for ovarian cancer: a case of primary peritoneal carcinoma. ( 26023675 )
2015
12
Primary Peritoneal Carcinoma Initially Presenting as Atypical Cervical Lymphadenopathy. ( 26120309 )
2015
13
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. ( 26026738 )
2015
14
Low-grade serous primary peritoneal carcinoma incidentally found in a hernia sac. ( 25953339 )
2015
15
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). ( 26089092 )
2015
16
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). ( 26335594 )
2015
17
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma. ( 25913798 )
2015
18
Primary peritoneal carcinoma: regional cancer institute experience. ( 25419074 )
2014
19
Solitary primary peritoneal carcinoma arising from the omentum. ( 25017281 )
2014
20
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. ( 25016924 )
2014
21
A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube. ( 24403495 )
2014
22
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. ( 24798935 )
2014
23
Effect of Tubal Sterilization Technique on Risk of Serous Ovarian and Primary Peritoneal Carcinoma. ( 25316178 )
2014
24
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. ( 25056850 )
2014
25
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. ( 24709487 )
2014
26
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). ( 24903764 )
2014
27
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. ( 23146339 )
2013
28
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. ( 23435437 )
2013
29
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. ( 23791702 )
2013
30
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. ( 24073344 )
2013
31
A case of extraovarian primary peritoneal carcinoma in an oophorectomized-hysterectomized patient: a diagnostic dilemma. ( 23578412 )
2013
32
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. ( 24361733 )
2013
33
Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. ( 23748176 )
2013
34
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. ( 22960352 )
2013
35
Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III-IV Ovarian Serous Carcinoma. ( 22666209 )
2012
36
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22446624 )
2012
37
Cutaneous lymphangitis carcinomatosis metastasis of extra-ovarian primary peritoneal carcinoma. ( 22949038 )
2012
38
Isolated metastatic primary peritoneal carcinoma to the breast: a rare site of disease recurrence. ( 22391350 )
2012
39
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. ( 22772063 )
2012
40
Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT. ( 21394599 )
2012
41
Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. ( 22348438 )
2012
42
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. ( 22439406 )
2012
43
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22710075 )
2012
44
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. ( 22037316 )
2012
45
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22366594 )
2012
46
Comparison between peritoneal tuberculosis and primary peritoneal carcinoma: a 16-year, single-center experience. ( 22964319 )
2012
47
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. ( 22664059 )
2012
48
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22943879 )
2012
49
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. ( 22047770 )
2012
50
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22155262 )
2012

Variations for Primary Peritoneal Carcinoma

Cosmic variations for Primary Peritoneal Carcinoma:

9 (show all 17)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10794 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 7
2 COSM43989 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.596G>A p.G199E 7
3 COSM44764 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.673G>T p.V225F 7
4 COSM44683 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 7
5 COSM10662 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.743G>A p.R248Q 7
6 COSM44603 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.835G>A p.G279R 7
7 COSM44684 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 7
8 COSM43850 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>C p.Y220S 7
9 COSM44338 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 7
10 COSM10758 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>G p.Y220C 7
11 COSM44769 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.755T>C p.L252P 7
12 COSM43737 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.830G>A p.C277Y 7
13 COSM10704 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 7
14 COSM11073 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1024C>T p.R342* 7
15 COSM11071 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1009C>T p.R337C 7
16 COSM10988 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.772G>A p.E258K 7
17 COSM520 KRAS peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.35G>T p.G12V 7

Expression for Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for Primary Peritoneal Carcinoma

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CXCL10 CXCL8 EGFR ERBB2 FOLR3 IFNG
2
Show member pathways
13.58 CXCL10 CXCL8 EGFR ERBB2 IFNG IL10
3
Show member pathways
13.47 BRCA1 CXCL8 EGFR ERBB2 IFNG IL10
4
Show member pathways
13.2 CXCL10 CXCL8 EGFR ERBB2 IFNG IL10
5
Show member pathways
12.92 BRCA1 BRCA2 EGFR ERBB2 RET TP53
6
Show member pathways
12.65 BRCA1 BRCA2 EGFR ERBB2 PGR TP53
7
Show member pathways
12.48 EGFR ERBB2 IFNG IL10 TP53
8 12.44 BRCA1 BRCA2 ERCC1 TP53
9
Show member pathways
12.41 EGFR ERBB2 TP53 VEGFA
10 12.22 EGFR ERBB2 TP53 VEGFA
11 12.21 BRCA1 EGFR ERBB2 MIR195 TP53 VEGFA
12 12.09 EGFR IFNG TP53 VEGFA
13 12.07 CXCL8 IL10 RET VEGFA
14 11.99 BRCA1 BRCA2 EGFR TP53 VEGFA
15
Show member pathways
11.95 BRCA2 EGFR ERBB2 TP53 VEGFA
16 11.95 BRCA2 CXCL8 EGFR ERBB2 IFNG RET
17 11.89 CXCL8 IL10 TP53 VEGFA
18 11.83 CXCL8 IFNG IL10
19 11.83 EGFR ERBB2 IFNG VEGFA
20 11.82 BRCA1 BRCA2 ERCC1
21
Show member pathways
11.8 EGFR ERBB2 VEGFA
22 11.79 CXCL8 IFNG VEGFA
23
Show member pathways
11.74 BRCA1 BRCA2 TP53
24 11.73 CXCL8 IFNG TP53
25 11.64 BRCA1 ERBB2 ERCC1 TP53
26 11.63 BRCA1 ERBB2 TP53
27 11.63 CXCL10 CXCL8 EGFR IFNG TP53
28
Show member pathways
11.6 CXCL8 IFNG VEGFA
29 11.57 EGFR ERBB2 RET TP53
30 11.52 BRCA1 CXCL8 IFNG
31 11.48 EGFR IFNG TP53
32 11.46 CXCL10 CXCL8 IL10
33 11.45 CXCL8 IFNG IL10
34 11.43 EGFR RET VEGFA
35 11.33 BRCA1 CXCL8 TP53 VEGFA
36 11.22 CXCL8 EGFR ERBB2 TP53 VEGFA
37 10.95 CXCL10 CXCL8 EGFR ERBB2 IL10

GO Terms for Primary Peritoneal Carcinoma

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.96 CXCL10 CXCL8 IFNG IL10 VEGFA
2 cell proliferation GO:0008283 9.89 BRCA2 EGFR ERBB2 ERCC1 TP53
3 cell surface receptor signaling pathway GO:0007166 9.87 CXCL10 EGFR ERBB2 IFNG
4 positive regulation of transcription, DNA-templated GO:0045893 9.85 BRCA1 BRCA2 EGFR IL10 RET TP53
5 positive regulation of cell migration GO:0030335 9.81 CXCL10 EGFR RET VEGFA
6 positive regulation of protein phosphorylation GO:0001934 9.76 EGFR ERBB2 IFNG VEGFA
7 wound healing GO:0042060 9.75 EGFR ERBB2 TP53
8 double-strand break repair GO:0006302 9.72 BRCA1 BRCA2 ERCC1
9 positive regulation of epithelial cell proliferation GO:0050679 9.71 EGFR ERBB2 VEGFA
10 positive regulation of MAP kinase activity GO:0043406 9.7 EGFR ERBB2 VEGFA
11 positive regulation of leukocyte migration GO:0002687 9.61 TP53 VEGFA
12 nucleotide-excision repair GO:0006289 9.61 BRCA2 ERCC1 TP53
13 negative regulation of ERBB signaling pathway GO:1901185 9.6 EGFR ERBB2
14 induction of positive chemotaxis GO:0050930 9.59 CXCL8 VEGFA
15 response to molecule of bacterial origin GO:0002237 9.58 CXCL8 IL10
16 response to gamma radiation GO:0010332 9.5 BRCA2 CXCL10 TP53
17 negative regulation of mitotic cell cycle GO:0045930 9.43 EGFR IL10 MIR195
18 chordate embryonic development GO:0043009 9.4 BRCA1 BRCA2
19 response to X-ray GO:0010165 9.33 BRCA2 ERCC1 TP53
20 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 BRCA1 BRCA2 TP53
21 positive regulation of gene expression GO:0010628 9.1 BRCA1 ERBB2 IFNG RET TP53 VEGFA
22 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 BRCA1 CXCL10 EGFR IL10 PGR TP53

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.5 EGFR ERBB2 TP53
2 protein C-terminus binding GO:0008022 9.46 BRCA2 ERBB2 ERCC1 TP53
3 damaged DNA binding GO:0003684 9.43 BRCA1 ERCC1 TP53
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.37 EGFR ERBB2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR ERBB2 RET
6 cytokine activity GO:0005125 9.02 CXCL10 CXCL8 IFNG IL10 VEGFA

Sources for Primary Peritoneal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....